Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation

Next Previous
X
Search
Trial Profile

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan; Fludarabine; Methotrexate; Tacrolimus
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Essential thrombocythaemia; Graft-versus-host disease; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Oct 2012 Biomarkers information updated
    • 16 Jun 2009 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 23 Nov 2006 Status change from Initiated to Recruiting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top